Confocal analysis of hepatocellular long-chain fatty acid uptake.
Transmembrane transport and cytosolic accumulation of fatty acids were investigated using confocal laser scanning microscopy (cLSM). A Zeiss LSM 310 system was used to determine the uptake of the fluorescent fatty acid derivative 12-(N-methyl)-N-[(7-nitrobenz-2-oxa-1,3- diazol-4-yl)amino]octadecanoic acid (12-NBD stearate) (C18) in single rat hepatocytes. Uptake was a saturable process with a Michaelis-Menten constant value of 68 nM. Initial uptake velocity was dependent on extracellular presence of albumin and beta-lactoglobulin. Absence of albumin reduced uptake to 32 +/- 16% (P < 0.01) of control values. In the presence of unlabeled stearate, uptake of 12-NBD stearate was lowered to 49 +/- 12% (P < 0.01). Ion substitution experiments showed no sodium dependency of uptake. Increase in membrane potential led to a pronounced accumulation of the fatty acid derivative within the plasma membrane and in the adjacent cytoplasmic compartment, whereas membrane depolarization had no effect on uptake rates. In separate experiments line scans through representative hepatocytes were analyzed to generate "x-t" plots. 12-NBD stearate showed a fluorescence pattern with prominent staining of the area of the plasma membrane and the adjacent cytoplasm, dependent on the presence of extracellular albumin. For the hepatocellular cytosolic accumulation process of 12-NBD stearate a diffusion constant of 22.2 +/- 6.2 x 10(-9) cm2/s was calculated. In contrast to the long-chain fatty acid derivative 12-NBD stearate, short (C5)- and medium (C11)-chain fatty acids revealed no membrane interaction with hepatocytes. Erythrocytes also lacked a membrane interaction process for 12-NBD stearate. In conclusion, it was demonstrated that cLSM is capable of directly evaluating the cellular fatty acid uptake process at a subcellular level.
Elsing
C
C
Department of Medicine, University of Heidelberg, Germany.
Winn-Börner
U
U
Stremmel
W
W
D009327:4-Chloro-7-nitrobenzofurazan / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D000818:Animals; D001896:Boron Compounds / Q000493:pharmacokinetics; D004594:Electrophysiology; D004912:Erythrocytes / Q000378:metabolism; D005227:Fatty Acids / Q000493:pharmacokinetics*; D005456:Fluorescent Dyes; D007477:Ions; D008099:Liver / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D008297:Male; D018613:Microscopy, Confocal; D009994:Osmolar Concentration; D051381:Rats; D017208:Rats, Wistar; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D013228:Stearates / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics*; D013347:Subcellular Fractions / Q000378:metabolism; D013997:Time Factors
C095489:4,4-difluoro-4-bora-3a,4a-diaza-s-indacene; D001896:Boron Compounds; D005227:Fatty Acids; D005456:Fluorescent Dyes; D007477:Ions; D013228:Stearates; C060027:12-N-methyl-7-nitrobenzo-2-oxa-1,3-diazolamino stearate; D012710:Serum Albumin, Bovine; D009327:4-Chloro-7-nitrobenzofurazan